Drug Trial News RSS Feed - Drug Trial News

Vernakalant drug more effective than Ibutilide in treating recent-onset atrial fibrillation

Vernakalant drug more effective than Ibutilide in treating recent-onset atrial fibrillation

Vernakalant, a new drug for treating recent-onset atrial fibrillation, has proved to be considerably more effective than Ibutilide, an established drug in this indication. It was able to normalize patients' heart rhythm more rapidly and with fewer side-effects ocurring. This was revealed by a study conducted at the Department of Emergency Medicine at Medical University of Vienna/General Hospital that has recently been published in "Europace", a journal of the European Society of Cardiology. [More]
One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Adults with asthma who were treated with one-dose dexamethasone in the emergency department had only slightly higher relapse than patients who were treated with a 5-day course of prednisone. [More]
HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies. [More]
Two Ebola vaccine candidates show promise in clinical trial

Two Ebola vaccine candidates show promise in clinical trial

An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. [More]
New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

New clinical study to evaluate inexpensive drug to prevent type 1 diabetes

A clinical study evaluating a new hypothesis that an inexpensive drug with a simple treatment regimen can prevent type 1 diabetes will be launched in Dundee tomorrow. [More]
Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
New therapy strategy for liver disease shows initial measureable success with norUrso

New therapy strategy for liver disease shows initial measureable success with norUrso

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid (norUrso). [More]
Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists. [More]
First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab. [More]
LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center. [More]
Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer. [More]
Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone. [More]
Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface. [More]
AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme. [More]
Advertisement
Advertisement